Close Menu

NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Horizon Blue Cross Blue Shield of New Jersey for its Veristrat test.

Horizon BCBS of New Jersey, which covers 3.8 million people in that state, determined as of May 10, 2016 that the test was a medically necessary benefit for patients with non-small cell lung cancer. With the decision, Veristrat is now covered for roughly 205 million people in the US, Biodesix said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.